Cardiovascular Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Routine Care of Frail People with Type 2 Diabetes

被引：0
|
作者：
Kutz, Alexander
Gopalakrishnan, Chandrasekar
Kim, Dae H.
Patorno, Elisabetta
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-1082-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1082-P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
    Scheen, Andre J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 143 : 88 - 100
  • [32] Efficacy of GLP-1 receptor agonists and SGLT-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
    Azhie, A.
    Gupta, S.
    Misra, S.
    Chen, S.
    Meerasa, A.
    Dash, S.
    Woo, M.
    Bhat, M.
    TRANSPLANTATION, 2022, 106 (8S) : 103 - 103
  • [33] Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
    Longato, Enrico
    Di Camillo, Barbara
    Sparacino, Giovanni
    Gubian, Lorenzo
    Avogaro, Angelo
    Fadini, Gian Paolo
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
  • [34] Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
    Lugner, Moa
    Sattar, Naveed
    Miftaraj, Mervete
    Ekelund, Jan
    Franzen, Stefan
    Svensson, Ann-Marie
    Eliasson, Bjoern
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [35] Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
    Moa Lugner
    Naveed Sattar
    Mervete Miftaraj
    Jan Ekelund
    Stefan Franzén
    Ann-Marie Svensson
    Björn Eliasson
    Cardiovascular Diabetology, 20
  • [36] Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
    Khedagi, Apurva
    Hoke, Cara
    Kelsey, Michelle
    Coviello, Andrea
    Jones, W. Schuyler
    Jackson II, Larry R.
    Patel, Manesh R.
    McGarrah, Rob W.
    Pagidipati, Neha J.
    Shah, Nishant P.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 13
  • [37] Mortality Differences SGLT-2, DPP-4 Inhibitors and GLP-1 Receptor Agonists
    不详
    DIABETES STOFFWECHSEL UND HERZ, 2018, 27 (03): : 173 - 173
  • [38] The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
    Zengguang Kuang
    Ningning Hou
    Chengxia Kan
    Fang Han
    Hongyan Qiu
    Xiaodong Sun
    International Urology and Nephrology, 2023, 55 : 617 - 629
  • [39] Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
    Dadwani, Rahul S.
    Wan, Wen
    Skandari, M. Reza
    Huang, Elbert S.
    MDM POLICY & PRACTICE, 2023, 8 (02)
  • [40] Socioeconomic position and initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study
    Falkentoft, A. C.
    Andersen, J.
    Malik, M. E.
    Selmer, C.
    Gaede, P. H.
    Staehr, P. B.
    Hlatky, M. A.
    Fosboel, E.
    Koeber, L.
    Torp-Pedersen, C.
    Gislason, G. H.
    Gerds, T. A.
    Shou, M.
    Bruun, N. E.
    Ruwald, A. C.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2622 - 2622
12345